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Abstract: In addition to malignant neoplastic cells, cancer tissues also
include immune cells, fibroblasts, and endothelial cells, including an
abundant collection of growth factors, proangiogenic mediators, cyto-
kines, chemokines, and components of the extracellular matrix. The
main physiological function of the immune cells is to monitor tissue
homeostasis, to protect against invading pathogens, and to eliminate
transformed or damaged cells. Between immune cells and malignant
cells in the tumor stroma, there is in fact a complex interaction which
has significant prognostic relevance as the immune system has both
tumor-promoting and -inhibiting roles. In non-small cell lung cancer
(NSCLC), there is a marked infiltration of different types of immune
cells, and the distribution, tissue localization, and cell types are signif-
icantly associated with progression and survival. Cancer immunother-
apy has seen a significant progress during the last decade. An increased
understanding of the mechanisms by which lung cancer cells escape the
immune system, and the recognition of the key tumor antigens and
immune system components in tumor ignorance have led to the devel-
opment of several lung cancer vaccines. As the NSCLC prognosis in
general is dismal, one may hope that future immunotherapy may be an
effective adjunct to standard therapy, reversing immunologic tolerance
in the tumor microenvironment. This review reports on the tumor
stroma and in particular tumor-suppressing and -promoting roles of the
immune system. Furthermore, it presents recent literature on relevant
immune cell-related research in NSCLC.
Key Words: Tumor, Stroma, Tumor microenvironment, Immune
cells, In situ immunology, Lung cancer, NSCLC.
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Until recently, the principal focus in cancer research hasprimarily been the malignant cell. As cancers are not
solely neoplastic cells but harbor tumor microenvironments,
which may vary according to cancer type, the lack of research
interest in the tumor microenvironment has led to a signifi-
cant discrepancy between the profound knowledge on cancer
cell biology and more limited knowledge on which roles the
tumor microenvironment plays.
The predominant host cells recruited to and activated in
the tumor microenvironment are immune cells, fibroblasts,
and pericytes/endothelial cells. Furthermore, there is an abun-
dant collection of growth factors, proangiogenic mediators,
cytokines, chemokines, and components of the extracellular
matrix. The microenvironment can exert inhibitory effects on
even aggressive malignant cell, but during their progression,
tumor cells may circumvent these inhibitory signals and
instead exploit immune cells and others for their own bene-
fits, resulting in growth, invasion, and metastasis.1–3
Approximately 150 years ago, Virchow postulated that
inflammation is a predisposing factor of tumorigenesis. This
hypothesis was based on his observation that cancerous tissue
often arose at sites of chronic inflammation and that inflam-
matory cells were present in the resected tumors.4 In contrast,
Burnet5 proposed, in 1970, the concept of immunological
surveillance: the immune system spontaneously identifies and
eliminates cancer cells, thus protecting against tumor devel-
opment. Supporting Virchow’s hypothesis, epidemiological
studies have shown during the last decades that individuals
prone to chronic inflammatory diseases have an increased risk
of cancer development6 and that underlying infections and
inflammatory responses have been linked to 15 to 20% of all
cancer deaths worldwide.7
Although cancer-protective and cancer-promoting fea-
tures of the immune system have been described, accumulat-
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ing data indicate that tumor-associated immune responses in
established malignancies more likely contribute to tumor
growth, progression, and immunosuppression than they are to
establish an effective antitumor response.2,4,8 The molecular
pathways of cancer-associated inflammation are presently
being unraveled, identifying molecular targets, which may
lead to improved diagnosis and therapy.8 This review covers
the roles of immune cells in the tumor microenvironment in
general and in the non-small cell lung cancer (NSCLC)
microenvironment in particular. The possibility of immuno-
therapeutic targeting in the NSCLC microenvironment will
also be addressed.
IMMUNE CELLS AND THEIR ROLE IN NORMAL
TISSUE HOMEOSTASIS AND INFLAMMATION
Our immune system plays critical roles in maintaining
tissue homeostasis; facilitating debris scavenging, cell turn-
over, and tissue remodeling; and preventing infection and cell
transformation. It is composed of two distinct compartments
mediating innate and adaptive immune responses (Figure 1).
Each compartment has, through a diversity of cells and
soluble mediators, advanced communication networks, which
enable rapid and effective responses to tissue injury.
The Innate Immune System
It consists of the phagocytes (macrophages, neutro-
phils, and dendritic cells [DCs]), mast cells, eosinophils,
basophiles, natural killer (NK) cells, and NK T cells. The
innate immune system is the first line of defense against
foreign pathogens and transformed cells.
There are two major pathways for macrophage activa-
tion in vivo, M1 or M2 activation.10 Normally, macrophages
undergo M1 activation yielding potent immunologic effector
cells, whereas M2 macrophages suppress immune responses,
promote tissue remodeling and angiogenesis, and produce
growth and survival factors for tumor cells.10–12
In the acute response, macrophages, DCs, and mast
cells are primary effectors, as they are posted in the tissue.
Macrophages and mast cells immediately release soluble
mediators such as cytokines, chemokines, matrix metallopro-
teinases, reactive oxygen species, and bioactive mediators
(histamine), mediating mobilization of additional leukocytes,
angiogenesis, and tissue remodeling.8,13
NK cells (CD56CD3) play a major role in the
rejection of tumor cells or virus infected cells.14 NK T cells
(CD56CD3) are a subset of T lymphocytes but express a
variety of molecular markers typical for NK cells.15
The  T cells are distributed peripherally and consti-
tute an independent population of circulating lymphocytes
with specific functions. These cells are able to sense “patho-
gens” and induce DC maturation, functional activation, DC
migration, and antigen presentation.16,17
The Adaptive Immune System
An innate immune response leads to activation of the
adaptive immune system (B and T cells), provided direct
interactions with antigen presenting cells and a proinflamma-
tory environment. The two major T lymphocyte subsets are
(1) T helper cells (Th, CD4) and (2) cytotoxic T cells (CTL,
CD8). Lymphocytes express somatically generated, diverse
antigen-specific receptors allowing a flexible and broad rep-
ertoire of responses.18,19
Primary adaptive responses are slower than the innate
responses, as clonal expansion due to recognition of foreign
antigens is required.20,21
Combined Innate and Adaptive Immune
Responses
There is an interplay between the innate and adaptive
immune system through production of cytokines and antibod-
ies, interactions between DCs and lymphocytes, and activa-
tion of the complement system.9
DCs, key players in the interphase between innate and
adaptive immunity, take up foreign antigens, migrate to
lymphoid organs, and present these antigens to adaptive
immune cells. NK cells interact bidirectionally with DCs and
macrophages, promoting their maturation and eliminating
FIGURE 1. Schematic presentation of the interplay be-
tween innate and adaptive immunity. NK T cells and  T
cells play their roles in the crossroad between the innate and
adaptive immune system. The crosstalk between these im-
mune systems is mediated by complex interactions between
cells of both immune subsets and their soluble factors. The
innate immune system, i.e., the first line of immune defense,
regulates adaptive immune responses by the production of
cytokines, interactions between dendritic cells and lympho-
cytes, and activation of the complement system. The adap-
tive immune system modulates innate immune responses by
cytokine and antibody production. Adapted from Cancer Im-
munol Immunother.9 DCs, dendritic cells; NK, natural killer;
NT T cells, natural killer T cells.
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immature DCs, thus reciprocally regulating activation of NK
cells.22–24
THE IMMUNE SYSTEM AND CANCER
DEVELOPMENT
When tissue homeostasis is persistently perturbed as in
chronic inflammation, interactions between innate and adap-
tive immune cells, as well as composition of cells and
mediators, will change. The roles between these systems can
be reversed during chronic inflammation,2 as adaptive im-
mune responses may cause (1) ongoing and excessive acti-
vation of the innate system,25 (2) antibody deposition in
tissues resulting in recruitment of innate immune cells,26 and
(3) T lymphocyte dysfunction instead of activation.27 The
inability to properly regulate the innate and adaptive immune
system can result in excessive tissue remodeling, loss of
tissue architecture due to destruction, protein alterations and
genotoxic DNA damage due to oxidative stress, and subse-
quently increased cancer risk.2
Cancer Inflammation—Tumor Inhibiting or
Tumor Promoting?
The developing malignancy is normally associated with
inflammation. Tumor-associated inflammation is a chronic
process, which is not beneficial, but often unfavorable for the
host. Many immune cells of the tumor microenvironment
may be associated with the tissue disruption caused by
inflammatory agents or be a response to tumor growth. There
is, however, no clear association between the presence of any
individual innate or adaptive immune cell type and a defined
outcome in terms of malignancy or prognosis across various
tumors. Even within individual immune cell types, there are
opposing functions as CD4 T cells, CD8 T cells, macro-
phages, and NK T cells have either tumor-suppressive or
tumor-promoting properties, depending on tissue context and
cellular stimuli.2,3,28,29
It has been documented that immune escape is a fun-
damental trait of cancer.30 The interaction between a tumor
and its host immune system is suggested to follow three steps:
(1) elimination, in which the immune reaction eliminates
nascent tumor cells; (2) equilibrium, in which immune reac-
tions control tumor expansion and metastasis; and (3) escape,
when tumor cells have developed resistance to the host’s
immune system; a process termed “immunoediting”31 (Figure
2). Among several identified escape mechanisms, a major
role is played by changes in the expression and/or function of
human leukocyte antigens (HLAs) expressed by tumor cells,
because they may markedly affect the tumor cell-host im-
mune system interactions. Nonclassical HLA-G is implicated
in such immune escape mechanisms of tumor cells and
appears to be one of the most powerful molecules for sup-
pression of the innate and/or adaptive immune response, also
toward lung cancer.32,33
Immune Reaction—The Seventh Hallmark of
Cancer?
Today, the link between inflammation and cancer is
well documented.2,8,34 As signs of “smoldering” inflamma-
tion have been observed also in tumors without a causal
association to inflammation, inflammatory cells and media-
FIGURE 2. Integration of immunoediting and oncogenesis during cancer progression. Oncogenesis leads to transformed
cells, which are attacked by immune cells due to neoantigen presentation. This immune surveillance imposes a selection for
transformed cells that acquire tactics to escape control. Their genetic instability facilitates evolution of strategies for immune
evasion or suppression, which may tilt the tumor microenvironment from hostile to supportive for the transformed cells. At
one point, a state of equilibrium may be achieved, corresponding to a clinically occult dormant disease. Further iteration of
evasion mechanisms may ultimately drive immune suppression beyond the local microenvironment, accomplishing immune
escape and in this manner licensing invasive and metastatic behavior. Adapted from Oncogene.30
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tors appear to be present in the microenvironment of most
tumors irrespective of what prompted the development.6
Cancer has been defined by six hallmarks acquired
during tumor development that are self-sufficiency in growth
signals, insensitivity to growth-inhibitory signals, evasion of
apoptosis, limitless replicative potential, sustained angiogen-
esis and tissue invasion, and metastasis.35 Immune reaction
was proposed as the seventh hallmark of cancer by Zitvogel
et al.36 and has later been supported by others.37,38
PARADOXICAL ROLES OF TUMOR-
INFILTRATING LEUKOCYTES
Leukocyte infiltration is a cardinal feature of almost all
cancers, and the major constituents of these infiltrates include
tumor-associated macrophages (TAMs), mast cells, NK and
NK T cells, and T and B lymphocytes.
The presence of immune infiltrates, with varying con-
tent between different types of solid tumors and patients, has
been long established, but the prognostic value of these
components is still controversial. A critical issue will be to
understand where and how the immune cells are activated and
recruited to the tumor site. Dieu-Nosjean et al.39 found in
many of their NSCLC tumors that immune cells were orga-
nized in tertiary lymphoid structures, absent in the nontu-
moral lung. Using an indirect marker for these structures, the
authors found that adaptive immunity in lung cancers can be
initiated independent of secondary lymphoid organs. Tertiary
lymphoid structures such as bronchus-associated lymphoid
tissues have been described in fetal and infant lung but
disappear in the normal lung before adulthood.40,41 The au-
thors found that these tertiary lymphoid structures they
named tumor-induced bronchus-associated lymphoid tissue
were highly associated with a favorable outcome.
Moreover, leukocyte infiltration is linked to angiogen-
esis, and a positive association has been demonstrated be-
tween numbers of tumor-infiltrating innate immune cells and
numbers of blood vessels.42,43 In animal studies, angiogenesis
and tumor development can be limited by reducing innate
immune-cell infiltration.44–46 Furthermore, vascular endothe-
lial growth factor (VEGF) and related molecules are potent
monocyte attractants contributing to the recruitment of mono-
cytes in both primary tumors and metastatic niches.47–50
In the following, this chapter will primarily deal with
the accumulated evidence from several in vitro and animal in
vivo studies, indicating that most of these bone marrow-
derived cells can be involved in carcinogenesis and/or tumor
invasion and metastasis.51–54
The Innate Immune System
TAMs alone constitute a major component of the leu-
kocyte infiltrate in malignant tumors.55 In several epithelial
tumors, the content of TAMs has in general been linked to
poor prognosis (Table 1),56 and the protumoral functions of
TAMs are presented in Table 2.10 Also TAM-related cell
populations as TIE2-expressing monocytes, myeloid-derived
suppressor cells, myeloid DCs, and mast cells have been
TABLE 1. Markers and Functions of Immune Cells in the Tumor Microenvironment
Cell Type Functions in the Tumor Microenvironment References
TAM Classically activated macrophages (M1) contribute to tumor rejection, whereas alternatively activated
macrophages (M2) promote angiogenesis and tissue remodeling. TAMs, sharing M2
characteristics, are tumor promoting and associated with poor prognosis.
55–57, 64–66
MDSC Increased in almost all patients with cancer. Suppressive effect with respect to T cells. 28, 57, 58
MSC Infiltrate different human cancers. In animal models, they increase cancer cell dissemination. Also
found to be immunosuppressive, in part through inhibition of T-cell proliferation.
71–74
Mast cell Important for generating and maintaining innate and adaptive immune responses. Increased numbers
of mast cells correlate in some cases with poor prognosis. Have been implicated in angiogenic
switch in animal models.
57, 60
TEM Implicated in angiogenesis in animal models. Have been detected in human tumors and at low
frequency in the peripheral blood of cancer patients.
57, 61, 62
Neutrophil Neutrophil levels are increased in patients with colon, gastric, and lung cancer. Increased neutrophil
numbers are associated with poor prognosis in bronchioalveolar carcinoma. Neutrophils have been
associated with angiogenesis and metastasis in animal models.
57, 87
NK cell Effector lymphocytes of the innate immune system. Are cytotoxic to cancer cells. Important role in
immunosurveillance of cancer.
13, 80, 81
NK T Cell T cells cytotoxic to cancer cells and contribute to immunosurveillance of cancer. Type 2 NK T cells
have been reported to down-regulate tumor immunosurveillance and suppress antitumor responses.
29, 84, 85
T helper cells CD4 T helper cells aid CD8 T cells in tumor rejection. 2, 28, 87
Cytotoxic T cells CTLs are effector cells of adaptive immunity and specifically recognize and destroy cancer cells. 2, 87, 90
Regulatory T cells Treg cells are CD4 lymphocytes, characterized by presenting the phenotype CD25CD127-
Foxp3. Treg cells are a subset of T cells with the ability to suppress harmful immunological
reactions to self- and foreign antigens and have also been attributed to polarize immunity away
from an antitumor response, block CD8 T cell activation and NK cell killing.
2, 28, 86, 88, 90, 106
B cell B lymphocytes are essential mediators of the adaptive immune system, but in an animal model of
squamous cell carcinoma, it was demonstrated to promote malignancy.
44, 87
CTL, CD8 cytotoxic T cells; MDSC, myeloid-derived suppressor cells; MSC, mesenchymal stem cells; NK cells, natural killer cells; NK T cells, natural killer T lymphocytes;
TAM, tumor-associated macrophage; TEM, TIE2-expressing monocyte; TIE2, angiopoietin receptor; Treg cells, regulatory T cells.
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linked to a protumor inflammatory microenvironment (Table
1).28,45,57–63 TAMs and related cell types often have an M2
phenotype oriented toward promoting tumor growth, inva-
sion, angiogenesis, and metastasis and suppressing adaptive
immunity.47,55,57,61,64–68 These cells may actively inhibit an-
titumor adaptive immunity by inducing T-cell dysfunction
through direct cell-cell contact and by production of immu-
nosuppressive mediators.69–74 Using NSCLC specimen, the
prognostic role of general TAM infiltration in the tumors was
inconclusive.75–77 Nevertheless, when differentiating between
M1 and M2 phenotypes, M1 conferred a significantly better
prognosis, although M2 macrophage infiltration was most
prevalent.78,79
NK cells and NK T cells, both effector lymphocytes of
the innate immune system, have somewhat diverse effects in
cancer. NK cells have direct cytotoxic effect on cancer cells,
hitherto no known unfavorable effects in cancer development
and a favorable effect in immunosurveillance.14,80,81 In con-
trast, NK T cells have been reported to have paradoxical
effects during cancer development.82,83 NK T cells have been
reported to down-regulate tumor immunosurveillance against
transplanted tumors,84,85 and it has been argued for at least
two subsets of NK T cells, where type II NK T cells suppress
antitumor immune responses.29
The Adaptive Immune System
In clinically overt malignant tumors, effective adaptive
immune responses are suppressed through activation of var-
ious pathways. Despite the importance of T lymphocytes in
immunosurveillance and control of early tumor growth,
chronic tumor cell secretion of cytokines and other soluble
factors subsequently (1) induce, expand, and recruit Treg
cells to tumor sites, (2) stimulate mature and immature DCs
to provide antigenic stimulation and immunosuppressive cy-
tokines (interleukin-10, transforming growth factor-), and
(3) inhibit DC maturation.2,28,86–92 In fact, Treg cells from
patients with lung cancer were found to directly inhibit
autologous T-cell proliferation.93 In such a way, a high
percentage of Treg cells in various neoplasms creates an
immune-suppressive microenvironment that curb antitumor
immunity and promotes tumor growth.93–95 The favorable
effect of eliminating Treg cell functions has been demon-
strated in animal models, improving antitumor T-cell re-
sponses and inducing regression of experimental tumors.96,97
In 2005, de Visser et al.44 reported that also B lympho-
cytes may be associated with tumor promotion. They found
that genetic elimination of mature B and T lymphocytes in a
mouse model limited neoplastic progression, which failed to
recruit innate immune cells. Adoptive transfer of B lympho-
cytes or serum from the HPV16 mice into B- and T-cell-
deficient/HPV16 mice restored innate immune cell infiltration
into premalignant tissue and reinstated parameters for full
malignancy.
THE ROLE OF TUMOR MICROENVIRONMENT
IMMUNITY IN NSCLC
In lung cancer, the nontumoral stromal tissue comprises
fibroblasts and extracellular matrix components, endothelial
cells and angiogenesis, and inflammatory cells, which are
largely T cells, macrophages, and mast cells, whereas plasma
cells, NK cells, and DCs are relatively rare.98–100 Two thirds
are lymphocytes, of which 80% are T cells,99 expressing
various activation antigens such as CD25 and HLA-DR.101
HLA-G has been found to have immunosuppressive
and immunomodulatory roles in cancer development. Lately,
both tumor cell HLA-G and blood soluble HLA-G of patients
with NSCLC have been associated with increased stage,
immune suppressive effects on NK-cell-mediated cytolysis
and reduced survival.102,103 Its expression on tumors and how
it can be exploited in diagnosis and therapy have already been
discussed.104
Most translational studies within this field have in-
cluded relatively few cases, and the stromal component of
tumors has often been neglected. Until recently, there was
relatively limited knowledge about the specificity of immune
cells in the lung cancer stroma.105 In the following, we will
present available research data on in situ immunity in the
NSCLC tumor microenvironment.
Innate Immune System and NSCLC
Role of DCs
DCs are the most potent antigen presenting cells for
inducing primary immune responses to carcinoma and repre-
sent a heterogeneous group of cells, which express different
markers.107 In a large cohort of patients with resected
NSCLC, increasing numbers of stromal DCs were signifi-
cantly associated with increased disease-specific survival
(DSS).75 This corroborates previous studies in
NSCLC39,108,109 and studies in other cancer types.110–112 In
the French study,39 the density of mature DCs was found to
be a better predictor for clinical outcome than the other tested
variables.
TABLE 2. Protumoral Functions of Tumor-Associated
Macrophages (TAMs)
● Production of growth and survival factors of tumor cells
TGF, EGF, IL-6, and IFN-inducible chemokine CXCL8
IL-4 induced TAM-supplied cathepsin B and S
● Production of angiogenic factors
VEGF, PDGF, FGF2, IL-8, TNF, and other ELR-positive CXC
chemokines
● Degradation of extracellular matrix and tissue remodeling activity
Expression/release of MMPs, uPAR, and deposition of fibrin and
collagen
Liberation of matrix sequestered growth factors
● Suppression of adaptive immune responses
Production of immunosuppressive mediators (IL-10, PGE2, and TGF)
Low/absent immunostimulating cytokines (IL-12)
Release of chemokines (CCL17, CCL18, and CCL22) recruiting
noncytotoxic T cells (e.g., regulatory T cells)
CCLs and CXCLs, chemokines; EGF, epidermal growth factor; ELR, specific
amino acid sequence of glutamic acid-leucine-arginine before the first cysteine of the
CXC; FGF2, fibroblast growth factor; IFN, interferon; IL, interleukin; MMP, matrix
metalloprotein proteases; PDGF, platelet-derived growth factor; PGE2, prostaglandin
E2; TGF, transforming growth factor-; uPAR, urokinase receptor; VEGF, vascular
endothelial growth factor.
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Low VEGF expression/high DC infiltration and high
VEGF expression/low DC infiltration are prognostic ex-
tremes, with the latter leading to an appallingly poor NSCLC
survival.108 Moreover, human DCs, in vitro, produce trans-
forming growth factor- under the influence of lung cancer
cells, yielding altered DCs with an increased ability to gen-
erate Tregs suppressing T cells.113,114
Role of NK Cells
Several studies have demonstrated that NK cells are pri-
marily confined to the tumor stroma.75,115,116 Based on lung
tumors, normal lung tissues, and peripheral blood of patients
with untreated NSCLC, Carrega et al.115 found that the cytotoxic
potential of tumor-infiltrating CD56 NK cells isolated from
cancer tissues was lower than NK cells from peripheral blood or
normal lung tissue. Increasing numbers of tumor-infiltrating NK
cells in resected adeno- and squamous cell carcinomas were
associated with a favorable survival prognosis.117,118 In a large
stage I to IIIA NSCLC cohort, Al-Shibli et al.75 found that
increasing numbers of stromal CD56 NK cells were signifi-
cantly associated with improved DSS and appeared as a pow-
erful independent prognostic factor (hazard ratio, 0.43).
Role of Macrophages
It has been argued that macrophages may have a potential
dual role in lung cancer by supporting both host-defense and
tumor progression.99 In fact, lung cancer metastasis to bone and
muscles in an animal model could be inhibited by decreasing the
number of monocytes/macrophages in both peripheral blood and
tumor stroma.119
Assessing the total counts of CD68 macrophages, sev-
eral research groups have reported a favorable association be-
tween increasing tumor islet macrophages and NSCLC sur-
vival.76,77,109 Dai et al.109 found the number of macrophages in
both the tumor and stromal compartment to be independent
prognostic role and higher impact than mature DCs or CTL. In
contrast, Al-Shibli et al.75 did not find CD68 macrophages in
neither tumor nor stromal compartments of 335 NSCLC speci-
mens to correlate with survival. Studying good survival versus
poor survival NSCLC groups by identifying the immunological
phenotype of TAMs (M1 or M2 type), two independent research
groups found that the macrophages infiltrating the tumors were
predominantly of the M1 phenotype in patients with extended
survival, although type M2 dominated in the tumor tissues (70%
versus 30%).78,79 The M2 macrophage densities were not asso-
ciated with patients’ survival time.
Role of Mast Cells
In a previous NSCLC study, the density of mast cells
correlated with micro vessel density but not survival.120 In a
larger NSCLC cohort, sparse numbers of CD117 mast cells
were detected, solely in the stromal compartment, and without
prognostic relevance.121 Consistently, two other studies76,77 re-
ported a neutral prognostic role of mast cell density in stages I to
IV NSCLC tumors.
In patients with adenocarcinoma, a higher density of mast
cells correlated with improved survival.122 In contrast, however,
Takanami et al.123 found increased mast cell infiltration in lung
adenocarcinomas to be associated with angiogenesis and worse
prognosis. Mast cells have been regarded a double-edged sword
in cancer immunity, which may explain the variable results with
respect to prognostic significance.
Adaptive Immune System and NSCLC
Tumor-infiltrating lymphocytes are considered to indicate
level of host immunity toward tumor antigens.31 Lee et al.124
observed that a high peritumoral lymphoid index was an inde-
pendent favorable prognostic factor in patients with stage III
NSCLC.
Role of T Helper and Regulatory Lymphocytes
Studying the prognostic role of epithelial and stromal
CD4 helper T cells in patients with resected stages I to IIIA
NSCLC, the authors reported that increasing numbers of stromal,
but not epithelial, CD4 cells correlated significantly with im-
proved DSS and that a high density of stromal CD4 cells was a
favorable independent prognostic factor in these patients.125 Sim-
ilar CD4 cell results have been reported by others.126 Corrob-
orating the previous study by Hiraoka et al.,127 the Norwegian
study125 reported an augmented positive prognostic effect at
simultaneously high stromal density of CD8 cells, confirming
the immunological cooperation between these cell types. In two
somewhat smaller studies, Pelletier et al.128 found peritumoral B
and not T cells to yield a better NSCLC survival, whereas
Nakamura et al.129 concluded that neither the total number of
intraepithelial T cells nor its helper or cytotoxic subtypes had
any prognostic relevance in NSCLC.
The CD4 category of cells is heterogeneous as it, besides
effector cells, contains Treg cells (CD4, CD25, and
FOXP3), which mediate immune tolerance and suppression of
T-cell effects. The amount of Treg cells are higher in NSCLC
tumors than normal lung tissues,100 and in a murine model, Treg
cells appeared as a prerequisite for k-ras driven lung tumorigen-
esis.130 In resected NSCLC tumors, infiltrating Treg cells corre-
lated positively with intratumoral COX-2 expression and were
associated with recurrence.131 Moreover, patients with stage I
NSCLC who had a higher proportion of tumor Treg cells
relative to CTL had a significantly higher risk of recurrence.132
Nevertheless, COX-2/PGE2 inhibition suppresses Treg cell ac-
tivity and enhances antitumor responses in lung cancer.133
Role of Cytotoxic T Lymphocytes
In 335 patients with resected stages I to IIIA NSCLC,
Al-Shibli et al.125 found that increasing numbers of both epithe-
lial and stromal CD8 CTL correlated with an improved DSS.
Actually, an independent significant impact was observed only
in the stroma, not in the tumor epithelium. In the same cohort,
Donnem et al.134 detected that high tumor cell VEGF-A/VEGF
receptor-2 combined with low density of CD4 and CD8 cells
in the tumor stroma gave a massive increase in risk of death
(hazard ratio, 9.2). The favorable prognostic significance of
CD8 cells has been confirmed by others.76,109 Although
Hiraoka et al.127 reported that a tumor infiltration of CD8
cells alone had no prognostic significance, the concurrent
infiltration of both CD8 and CD4 cells had an independent
favorable effect.
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A high number of CD3 T cells (pan T cell marker
including CD4, CD8, subset of CD3CD56 NK T cells,
and CD4CD8 T cells) have been associated with increased
apoptosis in patients with NSCLC.135 Kataki et al.99 concluded
that CD3 cells in lung carcinoma result from recruitment of
circulating precursors rather than from local replication, which is
important when considering the possible therapeutic relevance
of these cells. From a recent study, Al-Shibli et al.121 reported
that an increasing number of stromal and epithelial CD3 T cells
was associated with a better DSS and, further, that a high stromal
density of CD3 T cells was an independent indicator for
survival, highlighting the significance of the stromal compart-
ment in cancer progression and survival. These findings are
supported by a previous study in 710 patients with primary lung
cancer.136
The CD8 cell-related findings suggested that these im-
mune cells can modify the tumor stroma and epithelium in ways
which reduces disease progression and metastasis. In the Nor-
wegian study,125 there was a significant association between
increased stromal CD8 cells and low prevalence of angiolym-
phatic invasion. This may indicate a protective role of CD8
cells in preventing vascular infiltration of tumor cells and thus
inhibiting progression and metastasis. Anyway, the beneficial
combined effect of CD8 and CD4 cells may be mediated
primarily by the tumor stroma.
Role of B Lymphocytes
Increasing numbers of epithelial and stromal CD20 B
lymphocytes correlate with DSS in patients with stages I to III
NSCLC125 but without an independent prognostic impact. Based
on these finding, it can be hypothesized that humoral immunity
play a role in NSCLC survival. Consistently, Pelletier et al.128
observed that the presence of peritumoral CD20 cells was a
positive prognosticator in NSCLC. Mechanisms that may ex-
plain the prognostic effect of peritumoral B cells are local
containment of tumor cells, reducing the incidence of occult
micrometastases and thereby prolonging survival by limiting
further tumor dissemination.128 Besides, antibodies produced by
B cells are important mediators of tumor cell killing by NK and
other inflammatory cells through antibody-dependent cell-medi-
ated cytotoxicity (ADCC). A functional deficiency of B lym-
phocytes in lung cancer is, on the other hand, considered to be
caused by inadequate T-cell help and excessive suppression by
T and non-T cells.137
THERAPEUTIC APPROACHES BASED ON
IMMUNE RESPONSE
Nuclear factor -light-chain-enhancer of activated B cells
seems to play an important role in determining the balance
between protumor and antitumor properties of macro-
phages,138,139 hence nuclear factor -light-chain-enhancer of
activated B cells may be targeted to “re-educate” M2 macro-
phages toward an antitumor modality. The concept that stimu-
lation of innate immunity can promote protective responses to
cancer is not new. In 1972, Ruckdeschel et al.140 reported that
immune stimulation, associated with the postoperative compli-
cation of empyema, was associated with a decreased risk of
recurrence of resected NSCLC. In addition, in vivo animal
studies supported the concept that nonspecific immune stimula-
tion with BCG had effect on lung tumors.141,142 The larger
clinical studies did not, however, show a benefit. Later, nonspe-
cific immunostimulatory interventions with cytokines as inter-
leukin-2, interferon , and tumor necrosis factor  also proved
ineffective in NSCLC.143
In 1998, Kerr et al.144 reported a comparison of 28
possibly regressing lung cancer tumors with 67 minimally to
highly inflamed control cases. The possibly regressing tumors
showed a significantly higher number of CD3 T cells, CD68
macrophages, and CD57 NK cells, indicating an immunophe-
notype resembling that seen in regressing malignant melanomas.
During the last decade, because of advances in immunology and
molecular biology, the interest in and development of therapeu-
tic tumor vaccines have increased.143,145 This potential treatment
modality in NSCLC has moved from using nonspecific immu-
nomodulatory agents to lung cancer-specific tumor antigens and
tumor-cell-derived vaccines.146 In randomized NSCLC phase II
trials, encouraging trends toward better survival has been limited
to the melanoma-associated antigen 3 and the antigen mucin
1.147–149 These positive results have prompted the launch of
randomized phase III trials.
Today there are several drugs that can target cancer-
related inflammation, such as chemokine-receptor antagonists,
cytokine-receptor antagonists, and COX-inhibitors. There are
ongoing early phase trials of antagonists of interleukin-6, inter-
leukin-6 receptor, and different chemokines for various epithe-
lial malignancies.8 Especially as tumor cells in general are
genetically instable and frequently become therapy resistant, an
optimal future treatment should be a combined attack on both
tumor cells and the tumor microenvironment (inflammatory
cells), possibly yielding better and more durable efficacy. The
future challenge will be to tip the balance from cancer promoting
to cancer-inhibiting inflammatory responses in established
malignancies.
CONCLUSION
In the NSCLC microenvironment, there is a complex
interaction between immune cells and tumor cells as well as
other stromal cells types and tissue constituents. A marked
infiltration in tumor of different types of immune cells has been
reported. The distribution of these cells and the expression of
different inflammatory molecules throughout the tumor mi-
croenvironment are, to various extents, related to tumor progres-
sion and survival. This interaction has a significant unfavorable
prognostic relevance as it may facilitate tumor-promoting pro-
cesses such as evasion from immunosurveillance, tumor growth,
invasion, angiogenesis, and metastasis. Increasing evidence
shows that the density of various immune cells in the tumor
stromal compartment, in particular, has significant prognostic
relevance for NSCLC survival.
Advances in immunology and molecular biology have led
to a rapid progress in the development of cancer immunother-
apy, and positive immunotherapy studies in NSCLC have led to
ongoing randomized phase III trials. The potential for reversing
tumor-supporting inflammation may be the start of an exciting
new era for anticancer therapies. For this, we need more knowl-
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edge and a deeper understanding of the processes involved in the
cancer-related chronic inflammation.
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